Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 6Phase 1/2 4Phase 3 2Phase 4 1

Status

Recruiting 2Not yet recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Diseases 1Prostate Cancer Metastatic 1Genital Diseases, Male 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 52Fluorouracil 52Magnetic Resonance Spectroscopy 50Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 44Leucovorin 39Drug Therapy 39Irinotecan 37Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Pluvicto × Clear all
NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting
3,360 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡